Holen Sie sich die Stockscreener-App
4.60
1.32%
0.06
Schlusskurs vom Vortag:
$4.54
Offen:
$4.56
24-Stunden-Volumen:
314.98K
Relative Volume:
1.46
Marktkapitalisierung:
$197.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.90M
KGV:
-8.6792
EPS:
-0.53
Netto-Cashflow:
$-19.80M
1W Leistung:
+6.98%
1M Leistung:
+27.42%
6M Leistung:
-23.71%
1J Leistung:
+31.81%
1-Tages-Spanne:
$4.35
$4.6331
1-Wochen-Bereich:
$3.65
$5.04
52-Wochen-Spanne:
$3.19
$6.8184
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
Firmenname
Diamedica Therapeutics Inc
Sektor
Branche
Telefon
(763) 496-5454
Adresse
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Vergleichen Sie DMAC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
4.60 | 184.40M | 0 | -19.90M | -19.80M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-24 | Fortgesetzt | Craig Hallum | Buy |
| 2023-06-22 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-04-09 | Eingeleitet | Oppenheimer | Outperform |
| 2021-02-17 | Eingeleitet | ROTH Capital | Buy |
| 2020-10-30 | Eingeleitet | Guggenheim | Buy |
| 2020-07-08 | Eingeleitet | Maxim Group | Buy |
| 2019-04-30 | Eingeleitet | Dougherty & Company | Buy |
| 2019-03-05 | Eingeleitet | Lake Street | Buy |
Alle ansehen
Diamedica Therapeutics Inc Aktie (DMAC) Neueste Nachrichten
DiaMedica Therapeutics Inc. Stock Analysis and ForecastOutperformance with explosive growth - jammulinksnews.com
Is DiaMedica Therapeutics Inc. a good long term investmentDynamic profit expansion - jammulinksnews.com
What drives DiaMedica Therapeutics Inc. stock priceExtraordinary market timing - jammulinksnews.com
What analysts say about DiaMedica Therapeutics Inc. stockFree Stock Market Knowledge Sharing - jammulinksnews.com
Diamedica Therapeutics shares rise 11.01% intraday after $30.1M private placement and positive trial results for DM199 in preeclampsia. - AInvest
DiaMedica Announces $30.1M Private Placement for DM199 - TipRanks
DiaMedica secures $30.1 million in private placement for clinical trials By Investing.com - Investing.com South Africa
DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline - Business Wire
DiaMedica Therapeutics (NASDAQ:DMAC) Price Target Raised to $12.00 - Defense World
DiaMedica shares drop 35% following InvestingPro’s overvalued warning By Investing.com - Investing.com India
DiaMedica gains on positive mid-stage trial data for lead drug in preeclampsia - MSN
What makes DiaMedica Therapeutics Inc. stock price move sharplyReliable High Profit Alerts - beatles.ru
DiaMedica stock price target raised to $12 from $10 at H.C. Wainwright - Investing.com
DiaMedica Therapeutics to be included in the Russell 2000 and 3000 indexes - MSN
DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer - BioSpace
DiaMedica Therapeutics reports interim results from DM199 study - TipRanks
DiaMedica Announces Positive Interim Results for DM199 Study - TipRanks
DiaMedica reports positive interim results for preeclampsia treatment - Investing.com
Why DiaMedica Therapeutics Inc. stock attracts strong analyst attentionVerified Return Tips - Newser
How DiaMedica Therapeutics Inc. stock performs during market volatilityValue Pick Scanner - Newser
3 Promising Penny Stocks With Market Caps Under $200M - simplywall.st
Trend Tracker for (DMAC) - news.stocktradersdaily.com
DiaMedica Therapeutics Inc.(NasdaqCM: DMAC) added to Russell 2000 Dynamic Index - MarketScreener
DiaMedica Therapeutics Inc.(NasdaqCM: DMAC) added to Russell 3000 Growth Index - MarketScreener
DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes - Business Wire
DiaMedica Therapeutics Insiders Up US$4.1m On US$9.00m Investment - simplywall.st
Millennium Management LLC Increases Holdings in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
42,212 Shares in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Purchased by Jane Street Group LLC - Defense World
Can DiaMedica Deliver A Breakthrough In Preeclampsia Treatment? - RTTNews
Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Increases By 38.3% - Defense World
Lake Street Keeps Their Buy Rating on Diamedica Therapeutics (DMAC) - The Globe and Mail
Northern Trust Corp Has $978,000 Holdings in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
DMAC: HC Wainwright & Co. Reiterates Buy Rating with $10 Price T - GuruFocus
DiaMedica Therapeutics’ (DMAC) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright holds DiaMedica stock Buy rating, $10 target - Investing.com
H.C. Wainwright holds DiaMedica stock Buy rating, $10 target By Investing.com - Investing.com India
Finanzdaten der Diamedica Therapeutics Inc-Aktie (DMAC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):